CTI BioPharma Corp (NASDAQ:CTIC) announced positive progress on its lead programs in addition to key business priorities for 2017. “Throughout 2016 we maintained …
CTI BioPharma Corp (NASDAQ:CTIC) announced that the full clinical hold (February 2016) implemented by the U.S.
CTI BioPharma Corp (NASDAQ:CTIC) announced that data from the randomized Phase 3 PERSIST-2 clinical trial comparing the investigational agent pacritinib, an oral multikinase …
CTI BioPharma Corp (NASDAQ:CTIC) announced that James A. Bianco, M.
CTI BioPharma Corp (NASDAQ:CTIC) announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with …
CTI BioPharma Corp (NASDAQ:CTIC) announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, …
CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the first quarter ended March 31, 2016. “We continue to believe in the potential of pacritnib …
Seadrill Ltd (NYSE:SDRL) is up nearly 4% in pre-market up to $4.35 after oil rebounded yesterday.
CTI BioPharma Corp (NASDAQ:CTIC) announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be …
CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the fourth quarter and full year ended December 31, 2015. “While we were disappointed and surprised …